Post-market Prospective Clinical Study of Nagor Perle Mammary Implants

NCT06013514 | Recruiting

• 1 other identifier: DM6 640 0101
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Patients can undergo breast implant surgery for multiple reasons; cosmetic and reconstructive being the primary indications. In order to confidently state safety and due to strict regulation on medical devices it is important to maintain a record of safety and performance with all medical implants. This study is designed to collect data on a new generation of smooth mammary implants to assess the long term performance and safety data on this type of gel-filled mammary breast implant. The two main complications of breast implants are capsular contracture and rupture; these complications can take years to develop. The study is designed to evaluate the occurrence of these two primary complication as well as other secondary complications over a period of 10 years. Patient follow up will be carried out pre-operatively and post operatively at 12 months and then 3, 5, 8 and 10 years thereafter. The study will be carried out over 10 years to adequately assess complications which may only occur over the lifetime of the device such as systemic complications

Conditions

Breast Reconstruction; Breast Reconstruction Following Mastectomy; Breast Revision; Breast Augmentation; Breast Reconstruction With Silicone Implants; Breast Reconstruction After Mastectomy; Breast Reconstruction Surgery; Breast Implants

Keywords

prospective; observational; non-comparative; post-marketing study; PMCF; Perle; Nagor; GCA

Outcome Measures

Primary Outcomes (2)

• Rate of capsular contracture (Baker grade III-IV)

  10 years post-surgery

• Rate of implant rupture

  10 years post-surgery

Secondary Outcomes (4)

• Rate of the secondary surgical procedures required for correction of complications

  10 years post-surgery

• Rate and frequency of local complications associated with the use of Nagor gel-filled mammary implants

  10 years post-surgery

• Patient satisfaction

  10 years post-surgery

• rate and frequency of any adverse events

  10 years post-surgery

Study Arms (1)

Smooth Silicone Breast Implant

Device: PERLE Sterile Smooth Opaque gel filled mammary implants

Interventions

PERLE Sterile Smooth Opaque gel filled mammary implants DEVICE

Sterile smooth opaque gel filled mammary implants will be implanted in adult women having breast surgery for either augmentation, reconstruction or revision surgery. Different ranges of implants will be used to suit patient needs

Smooth Silicone Breast Implant

Eligibility Criteria

• Age: 18 Years - 65 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Female 18-65 requiring breast surgery for iether augmentation, reconstruction or revision, meeting inclusion and non inclusion criteria

You may qualify if:

• Genetic female subjects aged ≥18 and ≤65
• Subjects who underwent single or bilateral breast implantation with the study device for one of the following reasons:-
• i) Primary breast reconstruction following mastectomy (both for one-stage or two-stage surgeries, including patients with previous radiotherapy and who have ADMs of animal origin (bovine, porcine)). ii) Primary breast augmentation (cosmetic surgery) with or without mastopexy iii) Breast revision surgery with or without mastopexy c) Subjects who have received a Nagor PERLE implant. d) Subjects who have provided informed consent and can adhere to the requirements of follow up appointments as per the study protocol.

You may not qualify if:

• Subjects undergoing implant augmentation with a BMI \> 30 and undergoing reconstruction with a BMI \>32.
• Subjects with autoimmune disease, lung fibrocystic disease, conditions that interfere with wound healing and blood clotting, a weakened immune system, reduced blood supply to the breast tissue or any other condition for which breast implants are contraindicated.
• Subjects who have participated in a clinical study which involve chemical or drug study within 3 months prior to surgery, with the exception of subjects who are participating in breast cancer related clinical studies.
• Subjects with insufficient tissue covering due to either radiation damage on the chest wall, tight thoracic skin grafts or radical resection of the pectoralis major muscle.
• Subjects who have ADMs of synthetic origin.
• Subjects who, in the Investigator's clinical opinion, have existing local or metastatic carcinoma of the breast that is unlikely to be fully excised at the time of insertion of the breast implant.
• Subjects with known previous history of a sensitivity to silicone who, in the opinion of the Investigator, are unsuitable for surgery.
• Subjects with an active infection who are unsuitable for surgery unless, in the opinion of the investigator, they are treated and cleared by the investigator.
• Subjects with a history of abscesses anywhere in the body who, in the opinion of the Investigator, are unsuitable for surgery.
• Subjects with a known history of compromised wound healing.
• Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.
• Women who are pregnant and/or current breast feeders who do not stop breast feeding within 3 months of getting breast implants
• Patients who have local recurrence or metastatic carcinoma at the time of insertion of breast implant

Sponsors & Collaborators

• GC Aesthetics: lead

Study Sites (1)

NHS Manchester

Manchester, United Kingdom, M13 9WL, United Kingdom

RECRUITING

Central Study Contacts

Clinical Affairs Manager

CONTACT

+44 (0)1236 780780; Perle10PMCF@gcaesthetics.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 22, 2023
• First Posted: August 28, 2023
• Study Start: June 1, 2024
• Primary Completion (Estimated): September 1, 2038
• Study Completion (Estimated): September 1, 2038
• Last Updated: July 11, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)